Deerfield Management Company, L.P. (Series C) Rezolute, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Rezolute, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 19,223 shares of RZLT stock, worth $85,157. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,223Holding current value
$85,157% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RZLT
# of Institutions
82Shares Held
39.7MCall Options Held
402KPut Options Held
19.4K-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$50 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.38MShares$10.5 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.11MShares$9.36 Million1.66% of portfolio
-
Marshall Wace, LLP London, X01.85MShares$8.17 Million0.01% of portfolio
-
Blackstone Inc New York, NY1.74MShares$7.73 Million0.02% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $172M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...